Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ACAT2 | Q9BWD1 | 1/20 | 0.32 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19523243 | 0.91 | ADRA1D (0.38) | ADRA1DADRA1AADRA1BHPGDACAT2 | |
| SCHEMBL19523282 | 0.90 | ADRA1D (0.35) | ADRA1DADRA1AADRA1BHPGD | |
| SCHEMBL19523238 | 0.90 | KAT2B (0.35) | ADRA1DADRA1AADRA1BHPGD | |
| SCHEMBL17757866 | 0.89 | HIF1A (0.39) | ACAT2POLBKMT2AALDH1A1 | |
| SCHEMBL19523285 | 0.88 | HIF1A (0.42) | ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL19523280 | 0.88 | ADRA1D (0.38) | ADRA1DADRA1AADRA1BACAT2POLB | |
| SCHEMBL17992076 | 0.84 | ACAT2 (0.32) | ACAT2KMT2A | |
| SCHEMBL19523284 | 0.84 | GPR39 (0.37) | ACAT2KMT2A | |
| SCHEMBL17757113 | 0.82 | ACAT2 (0.33) | ACAT2POLBKMT2A | |
| SCHEMBL19523291 | 0.82 | POLB (0.38) | HPGDPOLBKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48992-E1 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2022-03-29 | — | — | US | disclosed |
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
| US-10280179-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2019-05-07 | — | — | US | disclosed |
| US-20180065982-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-03-08 | — | — | US | disclosed |
| US-9802956-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MUNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | ADRA1D 2423/4885ADRA1A 2437/4885ADRA1B 2415/4885 |
| US-10280179-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | ADRA1D 3345/4885ADRA1A 3544/4885ADRA1B 3400/4885 |
| US-20180065982-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | AIFM2, BAD, AIFM1 | ADRA1D 3347/4885ADRA1A 3584/4885ADRA1B 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.